GlassScriptPhysician profile
Robert Wendel Naumann
NPI 1730196098
$221,026.48
in general payments reported to CMS, 2019-2025
21 companies · $15K in 2025
The $15K reported for 2025 was more than what 93% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $28K · 2021: $40K · 2022: $44K · 2023: $11K · 2024: $31K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $51K · Travel and Lodging: $3,496 · Food and Beverage: $3,173 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $50,659.97 |
| Travel and Lodging | $3,496.07 |
| Food and Beverage | $3,173.09 |
| Education | $108.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $47,187.74 | 2019-2025 | |
| Seagen INC. | $43,738.57 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $30,754.57 | 2019-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $23,947.64 | 2019-2025 | Keytruda |
| Glaxosmithkline, LLC. | $23,669.36 | 2020-2025 | Zejula, Jemperli |
| Ethicon US, LLC | $9,336.77 | 2019-2025 | Surgicel Nu-Knit, Enseal, Stratafix |
| Tesaro, INC. | $8,961.38 | 2019 | |
| Emd Serono Research & Development Institute, INC. | $6,025.00 | 2024 | |
| Genmab U.S., INC. | $6,011.08 | 2022-2025 | Epkinly |
| Medical Device Business Services, INC. | $5,400.84 | 2022-2025 | Harmonic, Enseal X1 |
| Clovis Oncology, INC. | $4,235.75 | 2019-2022 | |
| Abbvie INC. | $3,057.34 | 2025 | |
| Aadi Bioscience, INC. | $2,539.68 | 2023-2024 | Fyarro |
| Virtual Incision Corporation | $2,500.00 | 2024 | Mira |
| Novartis Pharmaceuticals Corporation | $2,166.50 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $880.00 | 2021 | |
| Genentech USA, INC. | $314.65 | 2019 | |
| Caris Mpi, INC. | $130.43 | 2025 | Mi Cancer Seek |
| Immunogen, INC. | $118.65 | 2024 | Elahere |
| Karyopharm Therapeutics INC. | $27.78 | 2024 | Xpovio |
| Corcept Therapeutics | $22.75 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Naumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.